Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 4, 2012, Pages 568-582

  Bajelan, Elmira ^a   Haeri, Azadeh ^a   Vali, Amir Masoud ^b   Ostad, Seyed Nasser ^c   Dadashzadeh, Simin ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868089602     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3sc7j     Document Type: Article

References (56)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002; 2: 48-58.
2. Reddy LH. Drug delivery to tumours: recent strategies. J Pharm Pharmacol, 2005; 57: 1231-1242.
3. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc), 2000; 65: 95-106.
4. Vaalburg W, Hendrikse NH, Elsinga PH, Bart J, van Waarde A. P-glycoprotein activity and biological response. Toxicol Appl Pharmacol, 2005; 207: 257-260.
5. Goda K, Bacso Z, Szabo G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets, 2009; 9: 281-297.
6. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst, 1997; 89: 917-931.
7. Chintamani, Singh JP, Mittal MK, et al. Role of pglycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study. World J Surg Oncol, 2005; 3: 61.
8. Ford JM, Hait WN. Pharmacologic circumvention of multidrug resistance. Cytotechnology, 1993; 12: 171-212.
9. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 2000; 11: 265-283.
10. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res, 2003; 48: 347-359.
11. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res, 1991; 196: 26-32.
12. Loor F. Valspodar: current status and perspectives. Expert Opin Investig Drugs, 1999; 8: 807-835.
13. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the Pglycoprotein antagonist PSC 833. J Clin Oncol, 2001; 19: 832-842.
14. Bates SE, Bakke S, Kang M, et al. A phase I/II study of infusional vinblastine with the Pglycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res, 2004; 10: 4724-4733.
15. Advani R, Saba HI, Tallman MS, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood, 1999; 93: 787-795.
16. McLeod HL. Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? Eur J Cancer, 1994; 30A: 2039-2041.
17. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicinmitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat, 2010; 119: 255-269.
18. Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci, 2011; 14: 67-77.
19. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res, 1994; 54: 3352-3356.
20. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res, 2001; 7: 223-225.
21. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine, 2006; 1: 297-315.
22. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci, 2008; 97: 4696-4740.
23. Wang J, Goh B, Lu W, et al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol Pharm Bull, 2005; 28: 822-828.
24. Wang JC, Liu XY, Lu WL, et al. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats. Eur J Pharm Biopharm, 2006; 62: 44-51.
25. Motahari Z, Etebary M, Azizi E. Studying the role of p-glycoprotein in resistance to tamoxifen in human breast cancer T47D cells by immunocytochemistry. Int J Pharmacol, 2005; 1: 12-17.
26. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta, 2004; 1663: 167-177.
27. Sadzuka Y, Takabe H, Sonobe T. Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release, 2005; 108: 453-459.
28. Haeri A, Sadeghian S, Rabbani S, Anvari MS, Boroumand MA, Dadashzadeh S. Use of remote film loading methodology to entrap sirolimus into liposomes: Preparation, characterization and in vivo efficacy for treatment of restenosis. Int J Pharm, 2011; 414: 16-27.
29. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1985; 812: 55-65.
30. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem, 1980; 104: 10-14.
31. Meure LA, Foster NR, Dehghani F. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech, 2008; 9: 798-809.
32. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta, 1993; 1151: 201-215.
33. Sadanand V, Kankesan J, Yusuf A, et al. Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro. Cancer Lett, 2003; 198: 21-27.
34. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 1999; 51: 691-743.
35. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev, 2004; 56: 185-229.
36. Patil RR, Guhagarkar SA, Devarajan PV. Engineered nanocarriers of doxorubicin: a current update. Crit Rev Ther Drug Carrier Syst, 2008; 25: 1-61.
37. Alberts DS, Muggia FM, Carmichael J, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol, 2004; 31: 53-90.
38. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol, 2004; 31: 36-52.
39. Robert NJ, Vogel CL, Henderson IC, et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol, 2004; 31: 106-146.
40. Webb MS, Johnstone S, Morris TJ, et al. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm, 2007; 65: 289-299.
41. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ, Cullis PR. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta, 1993; 1149: 329-338.
42. Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J Control Release, 2009; 139: 73-80.
43. Tardi PG, Gallagher RC, Johnstone S, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta, 2007; 1768: 678-687.
44. Betageri GV, Parsons DL. Drug encapsulation and release from multilamellar and unilamellar liposomes. Int J Pharm, 1992; 81: 235-241.
45. Haeri A, Sadeghian S, Rabbani S, Anvari MS, Erfan M, Dadashzadeh S. PEGylated estradiol benzoate liposomes as a potential local vascular delivery system for treatment of restenosis. J Microencapsul, 2012; 29: 83-94.
46. Nallamothu R, Wood GC, Kiani MF, Moore BM, Horton FP, Thoma LA. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. PDA J Pharm Sci Technol, 2006; 60: 144-155.
47. Vali AM, Toliyat T, Shafaghi B, Dadashzadeh S. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm, 2008; 34: 10-23.
48. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta, 1991; 1068: 133-141.
49. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res, 2001; 7: 243-254.
50. Zuidam, JZ., de Vrueh, R., Crommelin, DJA., Characterization of Liposomes. In: Torchilin VP, Weissig V. (eds.), Liposomes, a Practical Approach. Oxford University Press, New York, USA, pp 31-78, 2003.
51. Xiong Y, Guo D, Wang L, Zheng X, Zhang Y, Chen J. Development of nobiliside A loaded liposomal formulation using response surface methodology. Int J Pharm, 2009; 371: 197-203.
52. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry, 1996; 35: 2521-2525.
53. Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm, 2005; 59: 177-187.
54. Moribe K, Maruyama K, Iwatsuru M. Encapsulation characteristics of nystatin in liposomes: effects of cholesterol and polyethylene glycol derivatives. Int J Pharm, 1999; 188: 193-202.
55. Robinson AJ, Richards WG, Thomas PJ, Hann MM. Behavior of cholesterol and its effect on head group and chain conformations in lipid bilayers: a molecular dynamics study. Biophys J, 1995; 68: 164-170.
56. Lagerquist C, Beigi F, Karlen A, Lennernas H, Lundahl P. Effects of cholesterol and model transmembrane proteins on drug partitioning into lipid bilayers as analysed by immobilizedliposome chromatography. J Pharm Pharmacol, 2001; 53: 1477-1487.